In a groundbreaking development, a collaborative research team spearheaded by Professor Dong-Woo Cho from POSTECH’s Department of Mechanical Engineering, alongside Professor Jae Yon Won from Eunpyeong St. Mary’s Hospital’s Department of Ophthalmology and Visual Science, and Professor Joeng Ju Kim of the Department of Bioscience and Biotechnology at Hankuk University of Foreign Studies, has engineered a revolutionary retinal vein occlusion disease model. This model is built on a sophisticated retina-on-a-chip platform that integrates advanced 3D bioprinting technology with a novel hybrid retinal decellularized extracellular matrix (RdECM) bioink. Published in the prestigious journal Advanced Composites and Hybrid Materials, this study represents a significant leap forward in recapitulating the pathological microenvironment of RVO in vitro, providing a powerful tool to decode disease mechanisms and test therapeutic interventions.

The core innovation underlying this platform is the utilization of an integrated 3D bioprinting system that fabricates complex retinal tissue architectures incorporating both vascular and neural components. The hybrid RdECM bioink, derived from naturally decellularized retinal tissues, retains key biochemical cues essential for cellular physiologic behavior and tissue-specific microenvironments. By bioprinting this composite bioink into microfluidic chips, the researchers have successfully recreated a layered retina structure featuring endothelial-lined vasculature adjacent to neural retinal cells. Within this microengineered retina-on-a-chip, the team induced vascular occlusion events, mirroring the pathological blockages characteristic of RVO. This approach enabled the real-time observation of hallmark disease phenomena, including inflammatory responses, blood-retinal barrier dysfunction, and aberrant angiogenic processes.

One of the most striking outcomes of this model is its ability to faithfully reproduce the vascular leakage and edema extensively documented in clinical RVO cases. The bioprinted retinal vessels in the chip model displayed compromised selective permeability, reflecting the breakdown of endothelial junctions pivotal to maintaining retinal homeostasis in vivo. This barrier disruption facilitated direct visualization of edema and immune cell infiltration dynamics, offering unprecedented insights into the cross-talk between vascular endothelial cells and adjacent retinal neurons during RVO progression. The fidelity with which this system recapitulates human RVO pathology opens new avenues for investigating molecular mechanisms driving disease initiation and progression.

Beyond disease modeling, the retina-on-a-chip platform demonstrated remarkable utility in pharmacological testing. When exposed to standard-of-care drugs commonly employed for RVO management, the model exhibited drug response profiles aligning closely with clinical outcomes. For instance, aspirin administration effectively mitigated vascular endothelial damage, attenuating the extent of leakage and inflammation. Immunomodulatory treatment with dexamethasone reduced inflammatory signaling and tissue edema, while bevacizumab—a monoclonal antibody targeting VEGF—successfully suppressed abnormal neovascular proliferation. These congruent in vitro and clinical drug responses validate the platform’s potential as a preclinical assay system that bridges the gap between bench and bedside, enabling accurate evaluation of drug efficacy and safety.

This innovative approach reaffirms the power of organ-specific decellularized extracellular matrix bioinks in faithfully reproducing the intricate human tissue microenvironments needed for accurate disease modeling. The retinal dECM bioink not only provides a structural scaffold but also delivers essential biochemical and mechanical cues that drive cell differentiation, survival, and function, replicating the native retinal milieu. Such biomimicry is critical for developing meaningful organ-on-a-chip systems capable of mimicking the unique physiology of human tissues, thereby improving predictive accuracy in drug development and personalized medicine applications.

In addition to its pharmaceutical screening capabilities, the retina-on-a-chip RVO model heralds a new direction for mechanistic studies into retinal vascular biology and pathology. It offers a controlled platform to dissect the molecular pathways activated by venous occlusion, elucidate endothelial-neuronal interactions, and explore inflammatory and immune responses within the retinal tissue context. This granular understanding may reveal novel therapeutic targets and biomarkers, facilitating the design of next-generation interventions for retinal diseases.

An important facet of this bioengineered model is its potential to significantly reduce reliance on animal experimentation. Conventional in vivo RVO models, while informative, often suffer from species-specific differences that limit translational relevance. The human cell-based retina-on-a-chip circumvents these limitations, offering an ethically favorable, reproducible, and scalable system that enhances the fidelity of experimental outcomes. This aligns with ongoing efforts in biomedical research to embrace alternative methodologies that reduce animal use without compromising scientific rigor.

The convergence of mechanical engineering, ophthalmology, and biotechnology exemplified in this study underscores the multidisciplinary nature essential to advancing regenerative medicine and tissue engineering. The seamless integration of 3D bioprinting technology with biomaterial science and clinical ophthalmology is a testament to the collaborative spirit driving innovation in healthcare. Such cross-sector partnerships are pivotal for transforming laboratory discoveries into practical clinical solutions.

Looking forward, the research team envisions adapting this platform for personalized medicine applications by incorporating patient-derived cells to generate customized RVO models tailored to individual pathological characteristics. This approach could revolutionize disease monitoring and treatment selection, enabling the identification of optimal therapeutic regimens for specific patient profiles. Moreover, the platform’s modular design may facilitate modeling a range of retinal diseases beyond RVO, expanding its impact within the ophthalmic research community.

This pioneering work was made possible through robust support from the Alchemist Project of Korea’s Ministry of Trade, Industry and Energy, the National Program for Regenerative Medicine, the Young Researcher Program of the National Research Foundation of Korea, and funding from Hankuk University of Foreign Studies. Such investment highlights the strategic importance of advancing biomedical engineering research to address pressing healthcare challenges like vision loss and retinal diseases.

In sum, the development of this 3D cell-printed RVO model via an advanced retina-on-a-chip platform represents a milestone in ophthalmic disease modeling. The system’s high physiological relevance, ability to replicate complex disease phenotypes, and accurate predictive responses to therapeutics present transformative opportunities for accelerating drug development, elucidating disease mechanisms, and ultimately preserving vision for millions worldwide. As organ-on-a-chip technologies continue to evolve, innovations like this herald a future where patient-specific, biomimetic disease models become routine tools in personalized healthcare.

Subject of Research: Development of an advanced retina-on-a-chip model for retinal vein occlusion using 3D bioprinting and hybrid retinal decellularized extracellular matrix bioink.

Article Title: Development of a 3D cell-printed RVO model by advancing a retina-on-a-chip with hybrid retinal dECM bioink and an integrated 3D bioprinting system

News Publication Date: 1-Oct-2025

Web References:
DOI: 10.1007/s42114-025-01455-2

Image Credits: POSTECH

Keywords: Health and medicine, Biomedical engineering, Diseases and disorders, Vision disorders, Retinopathy, Cell structure, Extracellular matrix, Mechanical engineering, Materials engineering, Biomaterials, Physiology, Vascular biology

The retina operates as the body’s visual processor, converting light into neural signals relayed to the brain. Surgeons routinely undertake intricate tasks when addressing retinal issues, including repairing retinal detachment or delivering therapeutic agents for inherited retinal diseases. However, the delicacy of these procedures demands unparalleled precision, as surgeons face the daunting task of navigating an environment rife with potential disturbances, including involuntary hand movements and the inevitable motion caused by the patient’s breathing and blinking.

Recognizing the complexity of such surgical endeavors, the collaborative research team at the University of Utah has devised a robust solution: a head-mounted robotic system that markedly enhances surgical precision. By anchoring the robotic device to the patient’s head, the researchers ensure that any natural head movements are neutralized, thereby stabilizing the surgical field. This innovative approach allows the robot to maintain a consistent and reliable positional reference, significantly mitigating the risks associated with manual surgical operations.

One of the standout features of this robotic surgery device is its extraordinary capability to execute movements with unparalleled precision—down to a mere one micrometer. For comparison, this measurement is smaller than the width of a human hair and equivalent to the size of individual cells within the retina. Such remarkable accuracy is achieved by employing a sophisticated haptic interface that enables surgeons to manipulate the robot with natural hand movements while simultaneously scaling down these motions to match the minuscule scale of the surgery.

The research conducted by the team extends beyond theoretical modeling; they have put their innovation to the test using enucleated pig eyes. Publishing their findings in the prestigious journal Science Robotics, the researchers reported successful outcomes when utilizing the robotic system for subretinal injections. This critical step paves the way for refining treatment techniques meant for patients suffering from inherited retinal diseases—a condition which, if left untreated, can lead to severe vision impairments.

Gene therapy represents a promising frontier in treating retinal disorders, allowing researchers to potentially reverse the effects of inherited conditions such as retinitis pigmentosa. However, the delivery of such therapies remains a complex challenge, especially when targeting subretinal spaces that are both minuscule and precariously positioned between delicate layers of retinal cells. Hence, the introduction of the robotic device may represent an essential advancement in delivering these sophisticated treatments effectively and safely.

Another ground-breaking aspect of this invention lies in its potential to transform the patient experience during procedures. Traditionally, eye surgeries involving retinal injections often necessitate the use of general anesthesia due to the complexity and sensitivity of the involved processes. However, the head-mounted design of this robotic system opens the door for administering intravenous (IV) sedation as a viable alternative. This paradigm shift not only enhances patient comfort but also allows for a much quicker recovery time, ultimately leading to safer and more efficient surgeries.

As the research team prepares to transition their device from laboratory settings to clinical applications, they remain laser-focused on the interdisciplinary approach that has characterized their work. The collaboration between the mechanical engineers and ophthalmic specialists has proven essential in realizing this project’s goals. Each contribution, whether from engineers, chemists, or physicists, has shaped the robotic device into a formidable tool that promises to elevate the standards of care in retinal surgery.

While currently in the experimental phase, the potential implications of this robotic device extend far beyond the lab. Its successful integration into surgical practice could revolutionize ophthalmic interventions, ensuring that surgeons are equipped with the means to address increasingly complex treatment paradigms as they arise. The vision for the future of eye surgery appears bright and promising as innovations like this robotic device redefine what’s possible in the realm of retinal healthcare.

In the advent of promising technologies, what lies ahead for patients facing the harsh reality of vision loss presents a new ray of hope. This journey through experimental research underscores the significance of innovation in medicine as it stands on the brink of substantial breakthroughs that will ultimately enhance patient outcomes and advance the field of ophthalmic surgery as a whole.

The ongoing commitment toward refining and optimizing this robotic device continues to be guided by a shared mission: to improve the efficacy of retinal treatments and facilitate better surgical outcomes. As the team looks to the future, the routine promise of robotics within healthcare not only beckons for ongoing exploration but embodies the aspirations of countless patients yearning for effective therapies that restore vision and curb the progression of hereditary retinal ailments.

Undoubtedly, this venture encapsulates a successful story of collaboration, innovation, and the relentless pursuit of excellence—a narrative that will shape the future of eye surgery. As the surgical robot takes its steps closer to reality in operating rooms, the vision becomes clearer: to offer patients the best possible care through the seamless integration of cutting-edge technology and world-class expertise.

### Subject of Research:
Robotic assistance in eye surgery.

### Article Title:
Head-mounted surgical robots are an enabling technology for subretinal injections.

### News Publication Date:
19-Feb-2025.

### Web References:
(N/A)

### References:
(N/A)

### Image Credits:
Moran Eye Center, University of Utah.